Farmakoekonomiczne aspekty zastosowania immunoterapii alergenowej w leczeniu alergicznego nieżytu nosa i astmy

Allergic rhinitis is a most common allergic disease affecting 40% of the population. The impact of AR on health-related quality of life (QoL) and productivity results in a significant economic burden. Allergen immunotherapy is the only causative treatment of allergic rhinitis and asthma. However, it is still unclear whether AIT is more cost-effective than the other treatments of AR without long-term cost-effectiveness studies. There is a need for further economic evaluations comparing different ways of immunotherapy and immunotherapy with pharmacotherapy.